Supernus Pharmaceuticals, Inc. SUPN
42.66
(0.63)
(1.46%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow SUPN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.97 | 3.90 | 3.84 | 3.25 | |
P/FCF ratio |
39.07 | 63.18 | 37.09 | 161.27 | |
P/Operating CF |
(43.83) | 141.26 | 44.79 | (561.50) | |
P/B ratio |
2.57 | 2.64 | 2.77 | 2.62 | |
Price to Tangible BV |
8.80 | 7.64 | 7.33 | 6.11 | |
EV/Sales |
3.61 | 3.53 | 3.40 | 2.85 | |
EV/EBITDA |
53.85 | 91.49 | 72.65 | 0.00 | |
EV/Operating CF |
34.27 | 53.64 | 31.68 | 119.07 | |
EV/FCF |
35.62 | 57.17 | 32.83 | 141.56 | |
Quick Ratio |
1.37 | 1.47 | 1.51 | 1.68 | |
Current Ratio |
1.80 | 1.90 | 1.96 | 2.08 | |
Net Debt/EBITDA |
7.74 | (14.31) | (21.82) | 11.43 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.49 | 0.51 | 0.55 | 0.59 | |
Operating CF/Net income |
1.37 | (4.84) | (29.01) | 0.08 | |
Capex/Depreciation |
(0.01) | (0.02) | 0.00 | (0.02) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
15.29% | 13.15% | 18.99% | 13.45% | |
Selling, General and Administrative Expense of Revenue |
93.53% | 57.85% | 60.26% | 61.01% | |
Intangible Assets out of Total Assets |
0.52 | 0.48 | 0.45 | 0.41 | |
Share Based Compensation of Revenue |
4.07% | 4.56% | 4.08% | 3.94% | |
Graham Net Nets |
0.08 | 0.09 | 0.10 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.69%) | (1.37%) | (0.99%) | (4.13%) | |
Free Cash Flow Yield |
2.56% | 1.58% | 2.70% | 0.62% | |
Revenue per Share |
3.40 | 3.75 | 3.60 | 3.77 | |
Operating CF per Share |
(1.09) | 0.35 | 1.15 | (0.08) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(1.09) | 0.34 | 1.15 | (0.09) | |
Cash per Share |
4.97 | 5.47 | 6.67 | 6.41 | |
Shareholders Equity per Share |
18.56 | 18.81 | 18.68 | 17.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.56 | 18.81 | 18.68 | 17.76 | |
Free Cash Flow |
(61.79) | 19.43 | 66.52 | (5.38) | |
Working Capital |
263.26 | 306.01 | 357.65 | 376.12 | |
Capital Expenditures |
(0.13) | (0.43) | — | (0.57) | |
Net Current Asset Value |
223.80 | 253.25 | 307.66 | 326.61 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(23.49%) | (1.94%) | (1.10%) | (26.65%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
158.33 | 164.94 | 163.91 | 176.24 | |
Average Payables |
92.21 | 92.08 | 89.07 | 93.10 | |
Average Inventory |
71.69 | 68.34 | 68.24 | 63.97 | |
Average Assets |
1,381.23 | 1,410.36 | 1,424.01 | 1,405.26 | |
Average Common Equity |
1,028.41 | 1,048.72 | 1,053.76 | 1,047.56 |
Columns are period end dates